<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Wall, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew G Lee, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Trobe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 30, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2410105955"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Idiopathic intracranial hypertension (IIH) is also called pseudotumor cerebri. It is a disorder defined by clinical criteria that include symptoms and signs isolated to those produced by increased intracranial pressure (ICP; eg, headache, papilledema, double vision, transient visual obscurations, and vision loss), elevated ICP with normal cerebrospinal fluid (CSF) composition, and no other cause of intracranial hypertension evident on neuroimaging or other evaluations [<a href="#rid1">1</a>].</p><p>While once called "benign" intracranial hypertension to distinguish it from secondary intracranial hypertension produced by a neoplasm, it is not a benign disorder. Many patients suffer from intractable, disabling headaches, and there is a risk of severe, permanent vision loss in approximately 5 to 15 percent of patients.</p><p>Recommendations for the treatment of IIH are limited by only a few randomized controlled trials [<a href="#rid2">2,3</a>]. In addition, the natural history of IIH is variable, with some patients resolving within months, while in others, the condition is chronic or recurrent.</p><p>This topic will discuss the prognosis and treatment of IIH. The epidemiology, pathogenesis, clinical features, and diagnosis of this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/5254.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/5257.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H3367849961"><span class="h1">TREATMENT GOALS</span><span class="headingEndMark"> — </span>The treatment of patients with IIH has two major goals: the alleviation of symptoms (usually headache) and the preservation of vision.</p><p class="headingAnchor" id="H160831352"><span class="h1">IDENTIFYING PATIENTS AT RISK FOR VISION LOSS</span></p><p class="headingAnchor" id="H3825375770"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Studies have attempted to identify patients at risk of severe, permanent vision loss. Features that appear to identify such patients include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe papilledema</strong> – IIH patients with higher-grade papilledema, Frisén grades 3 to 5 (<a class="graphic graphic_table graphicRef73887" href="/d/graphic/73887.html" rel="external">table 1</a> and <a class="graphic graphic_picture graphicRef54781 graphicRef80991 graphicRef59423 graphicRef72175 graphicRef52170 graphicRef60928" href="/d/graphic/54781.html" rel="external">picture 1A-F</a>), have poor visual outcomes if not treated aggressively [<a href="#rid4">4,5</a>]. Absence of papilledema appears to identify patients at low risk of vision loss [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/5257.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis", section on 'Papilledema'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vision loss and visual symptoms</strong> – Significant vision loss (ie, vision loss that is noticeable to the patient) at presentation suggests a higher risk, while transient visual obscurations likely suggest an intermediate risk [<a href="#rid4">4-8</a>].</p><p></p><p class="bulletIndent1">In addition, patients who develop such symptoms despite treatment are at risk and may be appropriate for more aggressive interventions. (See <a class="local">'Interventions for severe or refractory disease'</a> below.)</p><p></p><p>Other risk factors more variably identified in studies include male sex, systemic hypertension, anemia, younger age or onset in puberty, more severe obesity or recent weight gain, and higher opening pressure on lumbar puncture [<a href="#rid6">6,9-14</a>].</p><p>The presence or absence of findings on magnetic resonance imaging does not appear to predict visual outcomes [<a href="#rid15">15</a>]. </p><p class="headingAnchor" id="H619195656"><span class="h2">Fulminant disease</span><span class="headingEndMark"> — </span>A subset of individuals with IIH have a more malignant or fulminant course with rapid development of vision loss within a few weeks of symptom onset [<a href="#rid16">16-18</a>]. This is generally apparent at presentation. Such patients present with a rapid progression of symptoms, severe papilledema (grade 3 or worse), substantial visual field and/or visual acuity loss, and/or more than 30 transient visual obscurations per month [<a href="#rid4">4</a>].</p><p>In these patients, more aggressive interventions to limit the severity of permanent vision loss are considered at the outset. Urgent temporizing measures may be employed as well. In one series, 13 of 79 patients presented with severe vision loss (visual field mean deviation of -7 decibels [dB] or worse); over half of such patients required surgical intervention [<a href="#rid8">8</a>]. (See <a class="local">'Interventions for severe or refractory disease'</a> below and <a class="local">'Urgent temporizing measures'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">MONITORING DURING TREATMENT</span><span class="headingEndMark"> — </span>Patients require regular ophthalmology follow-up visits until they stabilize. Follow-up visit intervals are individualized based on the severity, duration, and response to treatment of the clinical manifestations, but initially should be at least monthly in patients with moderate symptoms. Patients with chronic low-grade papilledema (grade 1) seldom worsen quickly and can be followed less frequently [<a href="#rid5">5</a>].</p><p>Each office visit should include a best corrected visual acuity, formal visual field testing, dilated fundus examination with optic disc photographs, and often optical coherence tomography (OCT) of the optic nerve, retinal nerve fiber layer, and macular ganglion cell layer [<a href="#rid6">6</a>]. Worsening vision is an indication for intensifying treatment. </p><p class="headingAnchor" id="H1578403986"><span class="h1">INITIAL TREATMENT FOR MOST PATIENTS</span><span class="headingEndMark"> — </span>Some patients with normal vision and minimal symptoms require no treatment other than monitoring; most others will require risk factor modification and medications (<a class="graphic graphic_algorithm graphicRef133278" href="/d/graphic/133278.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3458586388"><span class="h2">Address risk factors and comorbid conditions</span><span class="headingEndMark"> — </span>Any potential agents that might cause or worsen IIH (eg, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivatives) should be discontinued. However, this intervention alone may not be sufficient to manage IIH. (See  <a class="medical medical_review" href="/d/html/5254.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis", section on 'Medications'</a>.)</p><p>Similarly, patients should be questioned regarding symptoms of sleep apnea; diagnostic polysomnography and treatment of sleep apnea should follow where appropriate. Since during apneic periods cerebrospinal fluid (CSF) pressure increases [<a href="#rid19">19</a>], obstructive sleep apnea appears to be an aggravating factor in patients with IIH [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Weight loss</span><span class="headingEndMark"> — </span>A low-sodium weight reduction program, ideally in conjunction with a nutritionist or dietician, is recommended for all patients with obesity and IIH. An approach using motivational interviewing may be especially helpful. Weight loss appears to alleviate symptoms and signs in many but not all patients [<a href="#rid3">3</a>]. Because weight loss is difficult for many to achieve and also takes time to achieve, other treatments for IIH are required at the same time when there is visual loss present.</p><p>However, studies documenting benefit are limited to observations in patients who generally receive treatment with other interventions for IIH. These studies typically report that weight loss is associated with reductions in intracranial pressure (ICP) and/or papilledema [<a href="#rid5">5,21-25</a>]. As an example, in the IIH treatment trial (IIHTT), all patients were recommended a low-sodium weight reduction diet and lifestyle management, which were associated with a 6 percent weight loss and mean CSF pressure reduction of 50 mm water [<a href="#rid5">5</a>]. A smaller number of other studies report improvement in either symptoms or visual fields [<a href="#rid21">21,23</a>]; however, no study has shown an association with vision outcomes.</p><p>Medically supervised weight loss programs or surgically induced weight reduction (eg, gastric banding or gastric bypass procedures) may be necessary in patients with severe obesity. Case series of patients with IIH undergoing gastric surgery report improvement of IIH symptoms and signs including papilledema, headache, tinnitus, and CSF pressure [<a href="#rid26">26-30</a>]. These findings were observed over one to three years after surgery and were associated with mean weight loss of 45 to 58 kg. (See  <a class="medical medical_review" href="/d/html/586.html" rel="external">"Bariatric surgery for management of obesity: Indications and preoperative preparation"</a>.)</p><p>Weight gain may be a risk factor for recurrence of IIH. (See <a class="local">'Recurrence and long-term monitoring'</a> below.)</p><p>Weight loss also has other health benefits. (See  <a class="medical medical_review" href="/d/html/5371.html" rel="external">"Obesity in adults: Overview of management", section on 'Importance of weight loss'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Carbonic anhydrase inhibitors</span></p><p class="headingAnchor" id="H381600598"><span class="h3">Acetazolamide</span><span class="headingEndMark"> — </span>For initial treatment of patients with IIH who have vision loss and/or vision symptoms, we suggest the carbonic anhydrase inhibitor <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> (<a class="graphic graphic_algorithm graphicRef133278" href="/d/graphic/133278.html" rel="external">algorithm 1</a>).</p><p>Carbonic anhydrase inhibitors are believed to reduce the rate of CSF production and have been associated with modestly improved outcomes in patients with IIH [<a href="#rid5">5,31,32</a>]. </p><p>In a randomized trial of 165 patients with IIH and mild visual loss (the IIHTT), treatment with <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> was associated with modest improvements in a perimetric measurement of global visual field loss, along with improvements in papilledema grade, CSF pressure, and vision-related quality of life at six months [<a href="#rid5">5</a>]. More patients in the placebo group had poor visual outcome compared with those in the acetazolamide treatment group (six versus one).</p><p>Other observational evidence supports the use of <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a>. Lowered CSF pressure with acetazolamide has been documented in patients with IIH who underwent continuous ICP recordings [<a href="#rid33">33</a>]. Case series also suggest that in patients who can tolerate it, acetazolamide is successful in managing symptoms and stabilizing vision in 47 to 67 percent of patients [<a href="#rid34">34-36</a>]. In addition, in a long-term follow-up study of 54 patients, the average treatment duration for acetazolamide was 14 months [<a href="#rid37">37</a>]. While recurrent episodes of IIH occurred in 38 percent over a mean of 6.2 years of follow-up, no recurrences occurred in the setting of ongoing acetazolamide treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – In adult patients, we usually start with 500 mg twice per day and advance the dose as required up to 2 to 4 grams per day, as tolerated by the patient. The titration can be stopped if the desired outcome is reached. While many patients cannot tolerate more than 2 grams per day, 40 percent of subjects in the IIHTT reached the dose of 4 grams per day and tolerated it well, that is, it did not interfere with activities of daily living. In young children, the recommended starting dose is 25 mg/kg per day with a maximum dose of 100 mg/kg or 2 grams per day [<a href="#rid34">34</a>]. The extended-release formulation (Diamox sequels) may be better tolerated by patients who are intolerant of immediate-release <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> but may be more expensive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential contraindications</strong> – Although a sulfa allergy is reported to be a relative contraindication to <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> use, there is little clinical or pharmacologic basis for this recommendation. Nonetheless, it remains a concern for many clinicians. A true cross-reaction between sulfonamide antimicrobials and the sulfa moiety in acetazolamide and <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> is unlikely [<a href="#rid38">38</a>]. Before prescribing acetazolamide to patients who report a sulfa allergy, we discuss the risks and benefits of treatment considering the nature of the adverse reaction composing the reported sulfa allergy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have had major adverse reactions (eg, Stevens-Johnson syndrome, anaphylaxis), we usually consider that the risk precludes the use of <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a>. Allergy consultation or other desensitization protocols may be considered in these patients, but we have not employed these. (See  <a class="medical medical_review" href="/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, if the previous sulfa-related reaction was minor, we usually proceed with <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> treatment. We treated 27 patients who had a reported sulfa allergy (excluding those that reported a severe adverse reaction) with acetazolamide; only two patients suffered urticaria, and there were no severe allergic cross-reactions to sulfa [<a href="#rid38">38</a>]. Another case series documents uneventful administration of acetazolamide to three patients with reported sulfa allergy [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">Pregnancy, particularly the first 20 weeks, is often considered a relative contraindication to the use of <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a>, although limited information on safety is available. Teratogenic effects have been reported with high doses in animals, and a single case of a teratoma was seen in humans [<a href="#rid40">40,41</a>]. If we consider that the benefit of acetazolamide use outweighs potential risks, we do use it in pregnant patients after discussion with the patient and the obstetrician and after obtaining informed consent. Treatment options are somewhat limited in pregnancy as caloric restriction and the use of other diuretics are also relatively contraindicated during pregnancy [<a href="#rid42">42-44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Medication side effects of <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> include digital and oral paresthesias, anorexia, malaise, metallic taste, fatigue, nausea, vomiting, electrolyte changes, mild metabolic acidosis, and kidney stones. These are usually dose related. While many patients in the IIHTT experienced side effects of acetazolamide, quality-of-life measures were still higher in patients who received acetazolamide [<a href="#rid5">5</a>]. The IIHTT found monitoring of electrolytes during acetazolamide treatment is not necessary if acetazolamide is the only diuretic used.</p><p></p><p class="bulletIndent1">For patients who are unable to tolerate <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a>, <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> is an alternative.</p><p></p><p class="headingAnchor" id="H1968623961"><span class="h3">Topiramate and other agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> is an antiseizure medication that inhibits carbonic anhydrase activity. Its efficacy in the treatment of migraine headaches and its association with weight loss are features that make it an attractive potential therapeutic option in IIH. Case reports and one small unblinded study suggest that topiramate appears to have a similar efficacy to <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> with regard to visual field improvement and symptom relief [<a href="#rid45">45-49</a>]. </p><p>Other carbonic anhydrase inhibitors, such as <a class="drug drug_general" data-topicid="9625" href="/d/drug information/9625.html" rel="external">methazolamide</a> (Neptazane), can also be used in acetazolamide-intolerant patients. We occasionally have had apparent success with these agents.</p><p class="headingAnchor" id="H2935155083"><span class="h2">Adjunctive treatments</span></p><p class="headingAnchor" id="H8"><span class="h3">Loop diuretics</span><span class="headingEndMark"> — </span>For patients with persistent or worsening visual symptoms despite maximizing treatment with <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a>, we suggest the addition of <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> (20 to 40 mg per day for adults and 1 to 2 mg/kg per day in children) (<a class="graphic graphic_algorithm graphicRef133278" href="/d/graphic/133278.html" rel="external">algorithm 1</a>). [<a href="#rid34">34</a>]. The evidence supporting its use in IIH is anecdotal. In one report of eight children treated with combined therapy of acetazolamide and furosemide, all had a rapid clinical response with resolution of papilledema, reduction in the mean CSF pressure after the first week of treatment, and normalization of CSF pressure within six weeks of starting therapy [<a href="#rid50">50</a>]. In our experience, furosemide can be a useful agent, preferably as an adjunct to acetazolamide and sometimes as an alternative to acetazolamide. </p><p>The same considerations discussed above regarding sulfa allergy and <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> also apply to <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>. We, after discussion of risk and benefits with patients, use furosemide in patients whose prior reactions have not included Stevens-Johnson syndrome, anaphylaxis, or other severe reactions. Among 21 such patients treated with furosemide, no allergic reactions were noted [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Headache prophylaxis</span><span class="headingEndMark"> — </span>Patients with IIH can continue to have headaches despite improvement in papilledema and visual function. Medications used in the prophylactic treatment of migraine headaches are often used for headache management in IIH if other treatments described above are not effective in this regard [<a href="#rid51">51</a>]. Many patients with headaches and IIH have migraine or another headache syndrome that is not directly related to increased ICP. These syndromes should be identified early and treated, as they may persist following otherwise successful IIH treatment. The choice of agent is influenced by the propensity of some of these medications (eg, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, tricyclic antidepressants) to produce weight gain; however, weight gain can be mitigated by use of low doses and careful monitoring of weight. (See  <a class="medical medical_review" href="/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>.)</p><p>Analgesic overuse or rebound headaches may be common in patients with IIH [<a href="#rid51">51-53</a>]. Efforts should be made to avoid and treat this condition. (See  <a class="medical medical_review" href="/d/html/3340.html" rel="external">"Medication overuse headache: Etiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3341.html" rel="external">"Medication overuse headache: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H3478243919"><span class="h1">URGENT TEMPORIZING MEASURES</span><span class="headingEndMark"> — </span>Rare patients present with or develop rapidly progressive vision loss (ie, fulminant IIH). (See <a class="local">'Fulminant disease'</a> above.)</p><p>Treatment is urgent to preserve vision:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical therapy</strong> – <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">Acetazolamide</a> should be initiated promptly and can be rapidly titrated up to 4 grams per day divided into two doses. (See <a class="local">'Acetazolamide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Consultation for intervention </strong>–<strong> </strong>We refer such patients urgently for one of the interventions listed below. (See <a class="local">'Interventions for severe or refractory disease'</a> below.)</p><p></p><p>In addition, short-term temporizing measures can be employed in such patients until surgery can be performed [<a href="#rid54">54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – In the setting of acute visual loss, a short course of intravenous glucocorticoids may be useful as a temporizing measure prior to surgical intervention in fulminant IIH.</p><p></p><p class="bulletIndent1">One case series describes successful use of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (250 mg four times a day for five days followed by an oral taper) in conjunction with <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> in four patients with IIH and severe, acute visual loss [<a href="#rid17">17</a>]. We do not use glucocorticoids long term, as their use is complicated by rebound increased intracranial pressure (ICP). (See <a class="local">'Treatments with a limited role'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial lumbar punctures</strong> – Serial lumbar punctures or lumbar drainage can be a useful temporizing measure as a prelude to surgery [<a href="#rid43">43,44,55</a>]. However, these are not useful for long-term management of IIH in most patients. (See <a class="local">'Treatments with a limited role'</a> below.) </p><p></p><p class="headingAnchor" id="H13"><span class="h1">INTERVENTIONS FOR SEVERE OR REFRACTORY DISEASE</span></p><p class="headingAnchor" id="H650818873"><span class="h2">Indications for intervention</span><span class="headingEndMark"> — </span>Patients with IIH who appear to benefit from surgical intervention include those who fail, are intolerant to, or are noncompliant with maximum medical therapy (<a class="graphic graphic_algorithm graphicRef133278" href="/d/graphic/133278.html" rel="external">algorithm 1</a>). They have intractable headache and/or progressive visual loss. Such patients are the minority, less than 10 percent in one center, of patients treated for IIH [<a href="#rid56">56</a>]. Potential indications for surgical therapy include [<a href="#rid57">57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening visual field defect despite medical therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of visual acuity loss attributed to papilledema (ie, not due to serous detachment, macular edema, hemorrhage, or choroidal folds)</p><p></p><p>While deteriorating vision (as suggested by an abnormal visual acuity or worsening visual field deficits) is a universally accepted indication for surgical intervention, other potential considerations need to be balanced against the inherent risks of the surgical procedures and the uncertainties regarding their efficacy. Intractable headache may be an indication for surgical treatment, but most chronic headaches in IIH are from migraine, medication overuse, caffeine overuse, or other non-intracranial pressure (ICP)-related headaches. </p><p class="headingAnchor" id="H3387514019"><span class="h2">Choice of procedure</span><span class="headingEndMark"> — </span>The two main surgical procedures in IIH are optic nerve sheath fenestration (ONSF) and cerebrospinal fluid (CSF) shunting procedures. Cerebral venous sinus stenting is an alternative intervention for IIH. These treatments have not been compared in a single population. Indirect comparisons of their efficacy in case series are challenged by different indications considered for intervention and different outcome measures used [<a href="#rid56">56</a>]. </p><p>Clinicians should choose the surgical procedure based on local expertise. While several papers discuss the relative benefits of ONSF versus CSF shunting, an individualized approach based upon availability of surgeons and procedures and clinician preference is recommended [<a href="#rid56">56,58,59</a>]. The overall rate of visual improvement seems to be equivalent across all of the surgical treatment modalities, and there is insufficient evidence to recommend or reject any one surgical modality over another at this time [<a href="#rid59">59,60</a>]. </p><p>Some patients require both shunting and ONSF. </p><p class="headingAnchor" id="H15"><span class="h2">Optic nerve sheath fenestration</span><span class="headingEndMark"> — </span>ONSF appears to be an effective procedure in patients who have progressive vision loss despite medical therapy. It is usually performed using a medial orbital approach. The optic nerve sheath is identified and a window is cut in this sheath, allowing CSF egress into the orbit. ONSF can stabilize or improve visual loss due to papilledema in IIH [<a href="#rid3">3,61-72</a>]. In general, ONSF is an outpatient procedure, although it typically involves general anesthesia. The recovery time is typically same day.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In one of the largest published case series summarizing 158 operations in 86 patients, visual acuity stabilized or improved in 94 percent, while visual fields stabilized or improved in 88 percent [<a href="#rid72">72</a>]. These results are consistent with aggregated data from other smaller case series [<a href="#rid56">56,61-65,68-71,73</a>]. Patients with a less severe and a shorter duration of visual abnormality have better visual outcomes after ONSF [<a href="#rid74">74,75</a>].</p><p></p><p class="bulletIndent1">Preservation of vision is the primary goal of ONSF. While some patients experience headache relief after ONSF, many do not [<a href="#rid61">61,72</a>]. ONSF has been associated with improvement in patients with deteriorating vision loss despite a working shunt [<a href="#rid66">66,68,72</a>]. ONSF also appears to be safe and effective in children [<a href="#rid67">67,76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Complications of ONSF occur in as much as 40 to 45 percent of patients [<a href="#rid70">70,72,77,78</a>]. Most but not all of these are transient and nondisabling. The more common complications include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Temporary diplopia (due to injury to extraocular muscle, nerve, or blood supply) in 29 to 35 percent [<a href="#rid62">62,70,72</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Efferent pupillary dysfunction from ciliary ganglion damage can be seen after ONSF in up to 11 percent [<a href="#rid62">62,70,72,75</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vision loss in up to 11 percent [<a href="#rid70">70</a>]. This is usually transient but can be catastrophic and permanent in 1.5 to 2.6 percent [<a href="#rid68">68,70</a>]. Vision loss can result from vascular complications (central retinal or branch artery occlusion, choroidal infarction), trauma (eg, operative traction), infectious optic neuritis, orbital hematoma, hemorrhage into the optic nerve sheath causing compressive hematoma, and other operative events [<a href="#rid65">65,72,75,77-79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse </strong>– ONSF may fail after initial benefit, requiring repeat surgery in 7 to 32 percent of eyes, depending in part on the duration of follow-up; failure may occur within months or after several years [<a href="#rid64">64,69,72</a>]. Repeat surgery appears to have a similar rate of benefit to the original [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H650819776"><span class="h2">Shunting</span><span class="headingEndMark"> — </span>CSF shunting procedures include ventriculoperitoneal shunt (VPS) or lumboperitoneal shunt (LPS). At most centers, VPS is performed preferentially due to a higher complication rate with LPS. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Uncontrolled observations report that shunt placement can relieve headache, diplopia, papilledema, and visual loss in patients with IIH [<a href="#rid3">3,56,80-85</a>]. However, reported outcomes are mixed; some report that 95 to 100 percent achieve stabilization or remission of visual problems [<a href="#rid56">56,73,80-83</a>], while others note that vision continued to worsen in approximately 10 percent. While headache relief appeared to occur in almost all patients soon after shunting, in one case series, the benefit was not universally sustained, with nearly half of patients having recurrent severe headaches within three years of surgery, despite a working shunt [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Shunt failure requiring revision is the most common complication of LPS and occurs in approximately half of patients, with a few patients requiring multiple (10 to 38) shunt revisions [<a href="#rid80">80-84,86</a>]. In rare cases, shunt failure is accompanied by visual loss that can be rapid and severe [<a href="#rid87">87</a>]. Shunt failure in VPS appears less common, occurring in 6 of 32 (19 percent) in one series; however, reported rates vary considerably, in part depending on the duration of follow-up [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1">Other complications of shunting include shunt infection, abdominal pain, and overdrainage causing low pressure [<a href="#rid80">80-84,89,90</a>]. Rare complications include cerebellar tonsillar herniation and syringomyelia, subdural and subarachnoid hemorrhage, and bowel perforation [<a href="#rid89">89,91,92</a>].</p><p></p><p>More recently developed technologies using advanced imaging as well as endoscopic operative techniques have improved the ability of surgeons to place catheters in the ventricles of patients with IIH who do not have ventricular enlargement. Case series suggested that ventriculoperitoneal catheters may be less prone to shunt obstruction than LPS [<a href="#rid86">86,93-95</a>]. However, the risks for low pressure, infections, and other complications were similar to LPS, and requirements for shunt revision remained substantial at 40 to 60 percent.</p><p class="headingAnchor" id="H16"><span class="h2">Venous sinus stenting</span><span class="headingEndMark"> — </span>Venous sinus stenting is a relatively new and somewhat controversial treatment option for IIH. Its use results from the observation that many patients with IIH have apparent stenoses of the transverse venous sinus or other cerebral veins, although whether this is a primary or secondary phenomenon is uncertain. (See  <a class="medical medical_review" href="/d/html/5254.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis", section on 'Intracranial venous hypertension'</a>.)</p><p>A number of case series describe some centers' experience with venous stenting in patients with IIH who had apparent venous sinus obstruction on cerebral venography [<a href="#rid96">96-99</a>]. In a 2013 literature review that summarizes data on 143 patients treated with venous stenting, 88 percent of patients reported improvement of headache, and 87 percent had improved visual symptoms [<a href="#rid100">100</a>]. Subsequent studies report similar results [<a href="#rid99">99,101</a>]. However, among the individual series, the effects on vision were not consistently documented and follow-up was often limited. While the procedure was technically successful in 99 percent, 6 percent of patients had complications, including three patients with subdural hematomas requiring surgical decompression. Also, two patients were treated with thrombolytic therapy when an intraluminal thrombus was noted to develop postoperatively, despite anticoagulation treatment [<a href="#rid97">97</a>]. Other reported complications include retroperitoneal hemorrhage and contrast reactions; recurrent stenosis has also been reported [<a href="#rid99">99,101</a>].</p><p>We and others feel that further documentation of clinical benefit from venous stenting is required before this becomes a routine part of IIH treatment, but at some centers it has become a first-line consideration for IIH [<a href="#rid3">3,102</a>].</p><p class="headingAnchor" id="H843137962"><span class="h1">TREATMENTS WITH A LIMITED ROLE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – While used in rare situations as a temporizing measure prior to surgical intervention, we and others avoid using glucocorticoids for long-term management of IIH [<a href="#rid103">103</a>] for the following reasons [<a href="#rid57">57</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoids can cause weight gain that might worsen IIH.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Steroid withdrawal can cause severe rebound intracranial hypertension associated with marked visual loss.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There are significant systemic side effects from chronic glucocorticoids. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial lumbar punctures and lumbar drain</strong> – Although serial lumbar punctures have been advocated for the treatment of IIH, we suggest against this treatment for the following reasons [<a href="#rid104">104</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cerebrospinal fluid (CSF) reforms within six hours unless there is a CSF leak, making any treatment benefit of short-term duration only.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lumbar punctures are uncomfortable for most patients and painful for many.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lumbar punctures can produce complications (eg, low-pressure headaches, CSF leak, CSF infection, intraspinal epidermoid tumors).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with obesity, lumbar punctures are often technically difficult.</p><p></p><p class="bulletIndent1">However, as an exception, serial lumbar punctures or a lumbar drain can be used in patients who are pregnant who wish to avoid medical therapy [<a href="#rid43">43,44,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indomethacin</strong><strong> </strong>– Some reports suggest that <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> may have efficacy in the treatment of secondary intracranial hypertension (eg, traumatic brain injury, hepatic encephalopathy), presumably by causing cerebral vasoconstriction and reducing cerebral blood flow [<a href="#rid105">105</a>]. In one report of seven patients with IIH, intravenous administration of 50 mg indomethacin was associated with prompt reduction in CSF pressure, and long-term treatment with 75 mg daily produced symptom relief and improvement in visual fields and papilledema grade [<a href="#rid106">106</a>]. Further study of this treatment is needed before it can be recommended for use in IIH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron </strong>– Iron supplementation in IIH patients with iron deficiency anemia appeared to be efficacious in a case series of six patients, and other reported cases suggest that treating anemia appears to be useful in some patients with IIH [<a href="#rid107">107</a>].</p><p></p><p class="headingAnchor" id="H2194494066"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H412592401"><span class="h2">Clinical course and outcomes</span><span class="headingEndMark"> — </span>No large prospective series describe the natural history of IIH. A protracted course lasting months to years appears to be common [<a href="#rid6">6,11,40,108,109</a>]. In most patients, symptoms worsen slowly if untreated. </p><p>With treatment, there is usually gradual improvement and/or stabilization. As symptoms stabilize, <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> can be tapered and withdrawn. Some patients have persistent papilledema, elevated intracranial pressure (ICP) as documented on lumbar puncture, and mild residual visual field deficits. </p><p>Permanent disabling vision loss is the major morbidity associated with IIH but is uncommon. While an early, hospital-based study found that 24 percent of 57 patients developed blindness or severe visual impairment [<a href="#rid9">9</a>], subsequent studies that have been outpatient based have found a lower rate of severe visual loss of 6 to 14 percent [<a href="#rid7">7,10,110</a>]. </p><p>Risk factors for vision loss are described above, but also include noncompliance with medication. (See <a class="local">'Risk factors'</a> above.)</p><p class="headingAnchor" id="H3586939149"><span class="h2">Recurrence and long-term monitoring</span><span class="headingEndMark"> — </span>A recurrence of symptoms may occur in 8 to 38 percent of patients after recovery from an episode of IIH or after a prolonged period of stability [<a href="#rid9">9,37,111,112</a>]. Weight gain is a common but not universal antecedent to recurrent IIH [<a href="#rid111">111,113</a>]. The time interval may be many years [<a href="#rid112">112</a>]. </p><p>Thus, patients should be followed for several years after recovery (<a class="graphic graphic_algorithm graphicRef133278" href="/d/graphic/133278.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with Frisén grade 2 papilledema or higher, we examine them every few to several months depending on the amount of visual loss and duration of stability. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with chronic Frisén grade 1 edema, we examine yearly or biyearly, as the risk of visual loss is low as long as they do not have an increase in their IIH symptoms.</p><p></p><p class="headingAnchor" id="H2561922"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/82902.html" rel="external">"Patient education: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment goals</strong> – The major morbidity associated with idiopathic intracranial hypertension (IIH) is vision loss. As much as 15 percent of individuals with IIH may be at risk of severe, permanent vision loss. Persistent headaches are also a source of disability and decreased quality of life. (See <a class="local">'Treatment goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Patients with IIH require regular follow-up visits with serial ophthalmology examinations until they stabilize. (See <a class="local">'Monitoring during treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – The approach to treatment is summarized in the algorithm (<a class="graphic graphic_algorithm graphicRef133278" href="/d/graphic/133278.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">Agents that might cause or worsen IIH (eg, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivatives) should be discontinued, and treatment provided as indicated for any potential comorbid conditions (eg, sleep apnea and anemia). (See <a class="local">'Address risk factors and comorbid conditions'</a> above.)</p><p></p><p class="bulletIndent1">Patients with obesity and IIH should be counseled and/or referred to make lifestyle changes to increase fitness and promote weight loss of 6 to 10 percent of body weight. (See <a class="local">'Weight loss'</a> above and  <a class="medical medical_review" href="/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p></p><p class="bulletIndent1">For initial treatment of patients with IIH, we suggest treatment with the carbonic anhydrase inhibitor <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). In one clinical trial, acetazolamide was associated with improvement of visual field function, papilledema grade, cerebrospinal fluid (CSF) pressure reduction, and vision-related quality-of-life measure at six months. <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> and other carbonic anhydrase inhibitors are alternatives to acetazolamide; experience with these agents is more limited. (See <a class="local">'Carbonic anhydrase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive treatments for persistent symptoms</strong> – <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">Furosemide</a> may provide an additional benefit to <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> in patients who experience continuing symptoms on acetazolamide. (See <a class="local">'Loop diuretics'</a> above.)</p><p></p><p class="bulletIndent1">Traditional headache therapies can be employed in symptomatic IIH patients. Analgesic rebound headache in particular is a common complication in IIH and should be prevented and treated as appropriate. (See <a class="local">'Headache prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulminant disease</strong> – Rare patients present with rapid development of vision loss within a few weeks of symptom onset. (See <a class="local">'Fulminant disease'</a> above.)</p><p></p><p class="bulletIndent1">Such patients require urgent initiation of <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> and referral for surgical intervention. (See <a class="local">'Interventions for severe or refractory disease'</a> above.)</p><p></p><p class="bulletIndent1">In such patients, we also suggest initiating a temporizing measure (eg, lumbar drain) until surgery is performed (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Urgent temporizing measures'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory or worsening disease </strong>– For unusual patients with IIH and progressing visual loss despite medical therapy, we recommend surgical intervention with optic nerve sheath fenestration (ONSF) and/or a CSF shunting procedure (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). The choice of surgical procedure is individualized based upon available expertise and patient preference. Patients who do not respond to one treatment may respond to the other. Neither intervention is a panacea; serious complications may occur. Failure and symptom recurrence are common. (See <a class="local">'Interventions for severe or refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis and follow-up</strong> – Most patients with IIH improve or stabilize with medical treatment over the course of several months. Recurrences may occur even after several years, necessitating ongoing monitoring. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Smith JL. Whence pseudotumor cerebri? J Clin Neuroophthalmol 1985; 5:55.</a></li><li><a class="nounderline abstract_t">Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005; :CD003434.</a></li><li><a class="nounderline abstract_t">Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83:488.</a></li><li><a class="nounderline abstract_t">Wall M, Falardeau J, Fletcher WA, et al. Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Neurology 2015; 85:799.</a></li><li><a class="nounderline abstract_t">NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M, McDermott MP, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014; 311:1641.</a></li><li><a class="nounderline abstract_t">Wall M. Sensory visual testing in idiopathic intracranial hypertension: measures sensitive to change. Neurology 1990; 40:1859.</a></li><li><a class="nounderline abstract_t">Rowe FJ, Sarkies NJ. Visual outcome in a prospective study of idiopathic intracranial hypertension. Arch Ophthalmol 1999; 117:1571.</a></li><li><a class="nounderline abstract_t">Mikkilineni S, Trobe JD, Cornblath WT, De Lott L. Visual Field Mean Deviation at Diagnosis of Idiopathic Intracranial Hypertension Predicts Visual Outcome. J Neuroophthalmol 2019; 39:186.</a></li><li><a class="nounderline abstract_t">Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39:461.</a></li><li><a class="nounderline abstract_t">Bruce BB, Preechawat P, Newman NJ, et al. Racial differences in idiopathic intracranial hypertension. Neurology 2008; 70:861.</a></li><li><a class="nounderline abstract_t">Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 ( Pt 1A):155.</a></li><li><a class="nounderline abstract_t">Stiebel-Kalish H, Kalish Y, Lusky M, et al. Puberty as a risk factor for less favorable visual outcome in idiopathic intracranial hypertension. Am J Ophthalmol 2006; 142:279.</a></li><li><a class="nounderline abstract_t">Bruce BB, Kedar S, Van Stavern GP, et al. Idiopathic intracranial hypertension in men. Neurology 2009; 72:304.</a></li><li><a class="nounderline abstract_t">Bruce BB, Kedar S, Van Stavern GP, et al. Atypical idiopathic intracranial hypertension: normal BMI and older patients. Neurology 2010; 74:1827.</a></li><li><a class="nounderline abstract_t">Saindane AM, Bruce BB, Riggeal BD, et al. Association of MRI findings and visual outcome in idiopathic intracranial hypertension. AJR Am J Roentgenol 2013; 201:412.</a></li><li><a class="nounderline abstract_t">Thambisetty M, Lavin PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68:229.</a></li><li><a class="nounderline abstract_t">Liu GT, Glaser JS, Schatz NJ. High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri. Am J Ophthalmol 1994; 118:88.</a></li><li><a class="nounderline abstract_t">Kidron D, Pomeranz S. Malignant pseudotumor cerebri. Report of two cases. J Neurosurg 1989; 71:443.</a></li><li><a class="nounderline abstract_t">Purvin VA, Kawasaki A, Yee RD. Papilledema and obstructive sleep apnea syndrome. Arch Ophthalmol 2000; 118:1626.</a></li><li><a class="nounderline abstract_t">Wall M, Purvin V. Idiopathic intracranial hypertension in men and the relationship to sleep apnea. Neurology 2009; 72:300.</a></li><li><a class="nounderline abstract_t">Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341:c2701.</a></li><li><a class="nounderline abstract_t">Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med 1974; 133:802.</a></li><li><a class="nounderline abstract_t">Kupersmith MJ, Gamell L, Turbin R, et al. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 1998; 50:1094.</a></li><li><a class="nounderline abstract_t">Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998; 105:2313.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Golnik KC, Aregawi D, et al. Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. Transl Res 2006; 148:215.</a></li><li><a class="nounderline abstract_t">Sugerman HJ, Felton WL 3rd, Salvant JB Jr, et al. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology 1995; 45:1655.</a></li><li><a class="nounderline abstract_t">Sugerman HJ, Felton WL 3rd, Sismanis A, et al. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg 1999; 229:634.</a></li><li><a class="nounderline abstract_t">Chandra V, Dutta S, Albanese CT, et al. Clinical resolution of severely symptomatic pseudotumor cerebri after gastric bypass in an adolescent. Surg Obes Relat Dis 2007; 3:198.</a></li><li><a class="nounderline abstract_t">Nadkarni T, Rekate HL, Wallace D. Resolution of pseudotumor cerebri after bariatric surgery for related obesity. Case report. J Neurosurg 2004; 101:878.</a></li><li><a class="nounderline abstract_t">Sun WYL, Switzer NJ, Dang JT, et al. Idiopathic intracranial hypertension and bariatric surgery: a systematic review. Can J Surg 2020; 63:E123.</a></li><li><a class="nounderline abstract_t">McCarthy KD, Reed DJ. The effect of acetazolamide and furosemide on cerebrospinal fluid production and choroid plexus carbonic anhydrase activity. J Pharmacol Exp Ther 1974; 189:194.</a></li><li><a class="nounderline abstract_t">Piper RJ, Kalyvas AV, Young AM, et al. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2015; :CD003434.</a></li><li><a class="nounderline abstract_t">Gücer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg 1978; 49:256.</a></li><li><a class="nounderline abstract_t">Matthews YY. Drugs used in childhood idiopathic or benign intracranial hypertension. Arch Dis Child Educ Pract Ed 2008; 93:19.</a></li><li><a class="nounderline abstract_t">Youroukos S, Psychou F, Fryssiras S, et al. Idiopathic intracranial hypertension in children. J Child Neurol 2000; 15:453.</a></li><li><a class="nounderline abstract_t">Warman R. Management of pseudotumor cerebri in children. Int Pediatr 2000; 15:147.</a></li><li><a class="nounderline abstract_t">Kesler A, Hadayer A, Goldhammer Y, et al. Idiopathic intracranial hypertension: risk of recurrences. Neurology 2004; 63:1737.</a></li><li><a class="nounderline abstract_t">Lee AG, Anderson R, Kardon RH, Wall M. Presumed "sulfa allergy" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol 2004; 138:114.</a></li><li><a class="nounderline abstract_t">Platt D, Griggs RC. Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies. Arch Neurol 2012; 69:527.</a></li><li><a class="nounderline abstract_t">Acheson JF. Idiopathic intracranial hypertension and visual function. Br Med Bull 2006; 79-80:233.</a></li><li><a class="nounderline abstract_t">Lee AG, Pless M, Falardeau J, et al. The use of acetazolamide in idiopathic intracranial hypertension during pregnancy. Am J Ophthalmol 2005; 139:855.</a></li><li><a class="nounderline abstract_t">Digre KB, Corbett JJ. Pseudotumor cerebri in men. Arch Neurol 1988; 45:866.</a></li><li><a class="nounderline abstract_t">Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. J Neurol 2002; 249:1078.</a></li><li><a class="nounderline abstract_t">Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology 1984; 34:721.</a></li><li><a class="nounderline abstract_t">Celebisoy N, Gökçay F, Sirin H, Akyürekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116:322.</a></li><li><a class="nounderline abstract_t">Pagan FL, Restrepo L, Balish M, et al. A new drug for an old condition? Headache 2002; 42:695.</a></li><li><a class="nounderline abstract_t">Shah VA, Fung S, Shahbaz R, et al. Idiopathic intracranial hypertension. Ophthalmology 2007; 114:617.</a></li><li><a class="nounderline abstract_t">Friedman DI, Eller PF. Topiramate for the treatment of idiopathic intracranial hypertension. Headache 2003; 43:592.</a></li><li><a class="nounderline abstract_t">Finsterer J, Földy D, Fertl E. Topiramate resolves headache from pseudotumor cerebri. J Pain Symptom Manage 2006; 32:401.</a></li><li><a class="nounderline abstract_t">Schoeman JF. Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol 1994; 9:130.</a></li><li><a class="nounderline abstract_t">Friedman DI, Rausch EA. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology 2002; 58:1551.</a></li><li><a class="nounderline abstract_t">Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema: a case-control study in a headache center. Neurology 1998; 51:245.</a></li><li><a class="nounderline abstract_t">Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology 1996; 46:1226.</a></li><li><a class="nounderline abstract_t">Bouffard MA. Fulminant Idiopathic Intracranial Hypertension. Curr Neurol Neurosci Rep 2020; 20:8.</a></li><li><a class="nounderline abstract_t">Evans RW, Friedman DI. Expert opinion: the management of pseudotumor cerebri during pregnancy. Headache 2000; 40:495.</a></li><li><a class="nounderline abstract_t">Fonseca PL, Rigamonti D, Miller NR, Subramanian PS. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol 2014; 98:1360.</a></li><li><a class="nounderline abstract_t">Corbett JJ, Thompson HS. The rational management of idiopathic intracranial hypertension. Arch Neurol 1989; 46:1049.</a></li><li><a class="nounderline abstract_t">Spitze A, Lam P, Al-Zubidi N, et al. Controversies: Optic nerve sheath fenestration versus shunt placement for the treatment of idiopathic intracranial hypertension. Indian J Ophthalmol 2014; 62:1015.</a></li><li><a class="nounderline abstract_t">Lai LT, Danesh-Meyer HV, Kaye AH. Visual outcomes and headache following interventions for idiopathic intracranial hypertension. J Clin Neurosci 2014; 21:1670.</a></li><li><a class="nounderline abstract_t">Kalyvas AV, Hughes M, Koutsarnakis C, et al. Efficacy, complications and cost of surgical interventions for idiopathic intracranial hypertension: a systematic review of the literature. Acta Neurochir (Wien) 2017; 159:33.</a></li><li><a class="nounderline abstract_t">Acheson JF, Green WT, Sanders MD. Optic nerve sheath decompression for the treatment of visual failure in chronic raised intracranial pressure. J Neurol Neurosurg Psychiatry 1994; 57:1426.</a></li><li><a class="nounderline abstract_t">Brourman ND, Spoor TC, Ramocki JM. Optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol 1988; 106:1378.</a></li><li><a class="nounderline abstract_t">Corbett JJ, Nerad JA, Tse DT, Anderson RL. Results of optic nerve sheath fenestration for pseudotumor cerebri. The lateral orbitotomy approach. Arch Ophthalmol 1988; 106:1391.</a></li><li><a class="nounderline abstract_t">Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. J Neuroophthalmol 1997; 17:86.</a></li><li><a class="nounderline abstract_t">Kelman SE, Heaps R, Wolf A, Elman MJ. Optic nerve decompression surgery improves visual function in patients with pseudotumor cerebri. Neurosurgery 1992; 30:391.</a></li><li><a class="nounderline abstract_t">Kelman SE, Sergott RC, Cioffi GA, et al. Modified optic nerve decompression in patients with functioning lumboperitoneal shunts and progressive visual loss. Ophthalmology 1991; 98:1449.</a></li><li><a class="nounderline abstract_t">Lee AG, Patrinely JR, Edmond JC. Optic nerve sheath decompression in pediatric pseudotumor cerebri. Ophthalmic Surg Lasers 1998; 29:514.</a></li><li><a class="nounderline abstract_t">Sergott RC, Savino PJ, Bosley TM. Modified optic nerve sheath decompression provides long-term visual improvement for pseudotumor cerebri. Arch Ophthalmol 1988; 106:1384.</a></li><li><a class="nounderline abstract_t">Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol 1993; 111:632.</a></li><li><a class="nounderline abstract_t">Plotnik JL, Kosmorsky GS. Operative complications of optic nerve sheath decompression. Ophthalmology 1993; 100:683.</a></li><li><a class="nounderline abstract_t">Hupp SL, Glaser JS, Frazier-Byrne S. Optic nerve sheath decompression. Review of 17 cases. Arch Ophthalmol 1987; 105:386.</a></li><li><a class="nounderline abstract_t">Banta JT, Farris BK. Pseudotumor cerebri and optic nerve sheath decompression. Ophthalmology 2000; 107:1907.</a></li><li><a class="nounderline abstract_t">Feldon SE. Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension. Neurosurg Focus 2007; 23:E6.</a></li><li><a class="nounderline abstract_t">Spoor TC, Ramocki JM, Madion MP, Wilkinson MJ. Treatment of pseudotumor cerebri by primary and secondary optic nerve sheath decompression. Am J Ophthalmol 1991; 112:177.</a></li><li><a class="nounderline abstract_t">Chandrasekaran S, McCluskey P, Minassian D, Assaad N. Visual outcomes for optic nerve sheath fenestration in pseudotumour cerebri and related conditions. Clin Exp Ophthalmol 2006; 34:661.</a></li><li><a class="nounderline abstract_t">Thuente DD, Buckley EG. Pediatric optic nerve sheath decompression. Ophthalmology 2005; 112:724.</a></li><li><a class="nounderline abstract_t">Brodsky MC, Rettele GA. Protracted postsurgical blindness with visual recovery following optic nerve sheath fenestration. Arch Ophthalmol 1997; 115:1473.</a></li><li><a class="nounderline abstract_t">Rizzo JF 3rd, Lessell S. Choroidal infarction after optic nerve sheath fenestration. Ophthalmology 1994; 101:1622.</a></li><li><a class="nounderline abstract_t">Mauriello JA Jr, Shaderowfsky P, Gizzi M, Frohman L. Management of visual loss after optic nerve sheath decompression in patients with pseudotumor cerebri. Ophthalmology 1995; 102:441.</a></li><li><a class="nounderline abstract_t">Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology 1997; 49:734.</a></li><li><a class="nounderline abstract_t">Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology 1996; 46:1524.</a></li><li><a class="nounderline abstract_t">Johnston I, Besser M, Morgan MK. Cerebrospinal fluid diversion in the treatment of benign intracranial hypertension. J Neurosurg 1988; 69:195.</a></li><li><a class="nounderline abstract_t">Chumas PD, Kulkarni AV, Drake JM, et al. Lumboperitoneal shunting: a retrospective study in the pediatric population. Neurosurgery 1993; 32:376.</a></li><li><a class="nounderline abstract_t">Rosenberg ML, Corbett JJ, Smith C, et al. Cerebrospinal fluid diversion procedures in pseudotumor cerebri. Neurology 1993; 43:1071.</a></li><li><a class="nounderline abstract_t">Lundar T, Nornes H. Pseudotumour cerebri-neurosurgical considerations. Acta Neurochir Suppl (Wien) 1990; 51:366.</a></li><li><a class="nounderline abstract_t">McGirt MJ, Woodworth G, Thomas G, et al. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg 2004; 101:627.</a></li><li><a class="nounderline abstract_t">Liu GT, Volpe NJ, Schatz NJ, et al. Severe sudden visual loss caused by pseudotumor cerebri and lumboperitoneal shunt failure. Am J Ophthalmol 1996; 122:129.</a></li><li><a class="nounderline abstract_t">Brune AJ, Girgla T, Trobe JD. Complications of Ventriculoperitoneal Shunt for Idiopathic Intracranial Hypertension: A Single-Institution Study of 32 Patients. J Neuroophthalmol 2021; 41:224.</a></li><li><a class="nounderline abstract_t">Chumas PD, Armstrong DC, Drake JM, et al. Tonsillar herniation: the rule rather than the exception after lumboperitoneal shunting in the pediatric population. J Neurosurg 1993; 78:568.</a></li><li><a class="nounderline abstract_t">Sell JJ, Rupp FW, Orrison WW Jr. Iatrogenically induced intracranial hypotension syndrome. AJR Am J Roentgenol 1995; 165:1513.</a></li><li><a class="nounderline abstract_t">Padmanabhan R, Crompton D, Burn D, Birchall D. Acquired Chiari 1 malformation and syringomyelia following lumboperitoneal shunting for pseudotumour cerebri. J Neurol Neurosurg Psychiatry 2005; 76:298.</a></li><li><a class="nounderline abstract_t">Suri A, Pandey P, Mehta VS. Subarachnoid hemorrhage and intracereebral hematoma following lumboperitoneal shunt for pseudotumor cerebri: a rare complication. Neurol India 2002; 50:508.</a></li><li><a class="nounderline abstract_t">Bynke G, Zemack G, Bynke H, Romner B. Ventriculoperitoneal shunting for idiopathic intracranial hypertension. Neurology 2004; 63:1314.</a></li><li><a class="nounderline abstract_t">Maher CO, Garrity JA, Meyer FB. Refractory idiopathic intracranial hypertension treated with stereotactically planned ventriculoperitoneal shunt placement. Neurosurg Focus 2001; 10:E1.</a></li><li><a class="nounderline abstract_t">Woodworth GF, McGirt MJ, Elfert P, et al. Frameless stereotactic ventricular shunt placement for idiopathic intracranial hypertension. Stereotact Funct Neurosurg 2005; 83:12.</a></li><li><a class="nounderline abstract_t">Owler BK, Parker G, Halmagyi GM, et al. Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement. J Neurosurg 2003; 98:1045.</a></li><li><a class="nounderline abstract_t">Higgins JN, Cousins C, Owler BK, et al. Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting. J Neurol Neurosurg Psychiatry 2003; 74:1662.</a></li><li><a class="nounderline abstract_t">Donnet A, Metellus P, Levrier O, et al. Endovascular treatment of idiopathic intracranial hypertension: clinical and radiologic outcome of 10 consecutive patients. Neurology 2008; 70:641.</a></li><li><a class="nounderline abstract_t">Ahmed RM, Wilkinson M, Parker GD, et al. Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. AJNR Am J Neuroradiol 2011; 32:1408.</a></li><li><a class="nounderline abstract_t">Puffer RC, Mustafa W, Lanzino G. Venous sinus stenting for idiopathic intracranial hypertension: a review of the literature. J Neurointerv Surg 2013; 5:483.</a></li><li><a class="nounderline abstract_t">Dinkin MJ, Patsalides A. Venous Sinus Stenting in Idiopathic Intracranial Hypertension: Results of a Prospective Trial. J Neuroophthalmol 2017; 37:113.</a></li><li><a class="nounderline abstract_t">Friedman DI. Cerebral venous pressure, intra-abdominal pressure, and dural venous sinus stenting in idiopathic intracranial hypertension. J Neuroophthalmol 2006; 26:61.</a></li><li><a class="nounderline abstract_t">Friedman DI, Jacobson DM. Idiopathic intracranial hypertension. J Neuroophthalmol 2004; 24:138.</a></li><li><a class="nounderline abstract_t">Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology 1983; 33:1386.</a></li><li><a class="nounderline abstract_t">Rasmussen M. Treatment of elevated intracranial pressure with indomethacin: friend or foe? Acta Anaesthesiol Scand 2005; 49:341.</a></li><li><a class="nounderline abstract_t">Förderreuther S, Straube A. Indomethacin reduces CSF pressure in intracranial hypertension. Neurology 2000; 55:1043.</a></li><li><a class="nounderline abstract_t">Biousse V, Rucker JC, Vignal C, et al. Anemia and papilledema. Am J Ophthalmol 2003; 135:437.</a></li><li><a class="nounderline abstract_t">Celebisoy N, Seçil Y, Akyürekli O. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand 2002; 106:367.</a></li><li><a class="nounderline abstract_t">Salman MS, Kirkham FJ, MacGregor DL. Idiopathic "benign" intracranial hypertension: case series and review. J Child Neurol 2001; 16:465.</a></li><li><a class="nounderline abstract_t">Radhakrishnan K, Ahlskog JE, Cross SA, et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993; 50:78.</a></li><li><a class="nounderline abstract_t">Taktakishvili O, Shah VA, Shahbaz R, Lee AG. Recurrent idiopathic intracranial hypertension. Ophthalmology 2008; 115:221.</a></li><li><a class="nounderline abstract_t">Shah VA, Kardon RH, Lee AG, et al. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. Neurology 2008; 70:634.</a></li><li><a class="nounderline abstract_t">Ko MW, Chang SC, Ridha MA, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011; 76:1564.</a></li></ol></div><div id="topicVersionRevision">Topic 5253 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3156890" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Whence pseudotumor cerebri?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034899" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Interventions for idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423118" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Update on the pathophysiology and management of idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26245929" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24756514" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2247234" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sensory visual testing in idiopathic intracranial hypertension: measures sensitive to change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10565536" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Visual outcome in a prospective study of idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153119" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Visual Field Mean Deviation at Diagnosis of Idiopathic Intracranial Hypertension Predicts Visual Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7103794" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18332344" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Racial differences in idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1998880" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Idiopathic intracranial hypertension. A prospective study of 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16876509" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Puberty as a risk factor for less favorable visual outcome in idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18923135" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Idiopathic intracranial hypertension in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20513819" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Atypical idiopathic intracranial hypertension: normal BMI and older patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23883223" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Association of MRI findings and visual outcome in idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224579" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fulminant idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023881" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2769395" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Malignant pseudotumor cerebri. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115256" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Papilledema and obstructive sleep apnea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18923134" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Idiopathic intracranial hypertension in men and the relationship to sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610512" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4821775" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pseudotumor cerebri treated by rice reduction diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9566400" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effects of weight loss on the course of idiopathic intracranial hypertension in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855165" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145568" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675222" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235521" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gastric surgery for pseudotumor cerebri associated with severe obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17324634" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical resolution of severely symptomatic pseudotumor cerebri after gastric bypass in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15540933" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Resolution of pseudotumor cerebri after bariatric surgery for related obesity. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32195557" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Idiopathic intracranial hypertension and bariatric surgery: a systematic review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4207244" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of acetazolamide and furosemide on cerebrospinal fluid production and choroid plexus carbonic anhydrase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26250102" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Interventions for idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/671078" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term intracranial pressure recording in the management of pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208981" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Drugs used in childhood idiopathic or benign intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10921516" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Idiopathic intracranial hypertension in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of pseudotumor cerebri in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534272" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Idiopathic intracranial hypertension: risk of recurrences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234289" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Presumed "sulfa allergy" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22158718" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242038" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Idiopathic intracranial hypertension and visual function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860291" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The use of acetazolamide in idiopathic intracranial hypertension during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3395260" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pseudotumor cerebri in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195458" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Idiopathic intracranial hypertension in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6539432" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pseudotumor cerebri and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17922725" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12482228" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A new drug for an old condition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17324704" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Topiramate for the treatment of idiopathic intracranial hypertension</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085265" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Topiramate resolves headache from pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8006361" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12034799" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Headache diagnoses in patients with treated idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9674810" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Idiopathic intracranial hypertension without papilledema: a case-control study in a headache center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628457" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Coexistence of migraine and idiopathic intracranial hypertension without papilledema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219578" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fulminant Idiopathic Intracranial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10849049" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Expert opinion: the management of pseudotumor cerebri during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24820047" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2679506" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The rational management of idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25449938" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Controversies: Optic nerve sheath fenestration versus shunt placement for the treatment of idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24974193" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Visual outcomes and headache following interventions for idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27830325" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy, complications and cost of surgical interventions for idiopathic intracranial hypertension: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964827" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Optic nerve sheath decompression for the treatment of visual failure in chronic raised intracranial pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3178548" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Optic nerve sheath decompression for pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3273487" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Results of optic nerve sheath fenestration for pseudotumor cerebri. The lateral orbitotomy approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176777" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Optic nerve sheath fenestration for pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1620303" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Optic nerve decompression surgery improves visual function in patients with pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1945323" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Modified optic nerve decompression in patients with functioning lumboperitoneal shunts and progressive visual loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9640576" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Optic nerve sheath decompression in pediatric pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3178549" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Modified optic nerve sheath decompression provides long-term visual improvement for pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8489443" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8493011" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Operative complications of optic nerve sheath decompression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3827717" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Optic nerve sheath decompression. Review of 17 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013197" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pseudotumor cerebri and optic nerve sheath decompression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18004968" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1867302" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of pseudotumor cerebri by primary and secondary optic nerve sheath decompression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970759" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Visual outcomes for optic nerve sheath fenestration in pseudotumour cerebri and related conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15808268" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pediatric optic nerve sheath decompression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366687" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Protracted postsurgical blindness with visual recovery following optic nerve sheath fenestration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090466" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Choroidal infarction after optic nerve sheath fenestration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891983" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Management of visual loss after optic nerve sheath decompression in patients with pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9305333" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Lumboperitoneal shunting for pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649541" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Lumboperitoneal shunt for the treatment of pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3392566" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cerebrospinal fluid diversion in the treatment of benign intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8455762" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Lumboperitoneal shunting: a retrospective study in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170543" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cerebrospinal fluid diversion procedures in pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2089940" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pseudotumour cerebri-neurosurgical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15481717" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8659591" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Severe sudden visual loss caused by pseudotumor cerebri and lumboperitoneal shunt failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32235226" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Complications of Ventriculoperitoneal Shunt for Idiopathic Intracranial Hypertension: A Single-Institution Study of 32 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450330" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Tonsillar herniation: the rule rather than the exception after lumboperitoneal shunting in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7484598" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Iatrogenically induced intracranial hypotension syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654065" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Acquired Chiari 1 malformation and syringomyelia following lumboperitoneal shunting for pseudotumour cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12577109" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Subarachnoid hemorrhage and intracereebral hematoma following lumboperitoneal shunt for pseudotumor cerebri: a rare complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477563" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Ventriculoperitoneal shunting for idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16749748" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Refractory idiopathic intracranial hypertension treated with stereotactically planned ventriculoperitoneal shunt placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15724109" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Frameless stereotactic ventricular shunt placement for idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12744365" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638886" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285539" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Endovascular treatment of idiopathic intracranial hypertension: clinical and radiologic outcome of 10 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799038" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22863980" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Venous sinus stenting for idiopathic intracranial hypertension: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556959" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Venous Sinus Stenting in Idiopathic Intracranial Hypertension: Results of a Prospective Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518170" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cerebral venous pressure, intra-abdominal pressure, and dural venous sinus stenting in idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15179068" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6684240" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15752400" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Treatment of elevated intracranial pressure with indomethacin: friend or foe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061268" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Indomethacin reduces CSF pressure in intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654358" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Anemia and papilledema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460143" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453440" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Idiopathic "benign" intracranial hypertension: case series and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418804" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166427" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Recurrent idiopathic intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285538" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536635" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
